Cannabis sativa extracts demonstrate potential to in COVID-19 treatment
By Akshay Kedari  Date: 2020-04-23

Cannabis sativa extracts demonstrate potential to in COVID-19 treatment

The University of Lethbridge, with Swysh, a company focused on cannabinoid R&D and Pathway Rx, a research company focused on developing custom cannabis therapies, are partnering to unravel a specific Cannabis sativa extract that shows potential as an additional treatment for the novel coronavirus.

Dr. Igor Kovalchuks, Chief Executive Officer at Pathway RX and Dr. Olga Kovalchuk, (both are professors at The University of Lethbridge) reportedly said that although one of their most successful cannabis sativa extracts require further validation in an animal model as well as in a large-scale analysis, the study is crucial for the examination of the effects of medical cannabis on coronavirus.

A team of researchers and Kovalchuks recently submitted their paper to a journal for publication. The paper represents extensive research study on the effects of medical cannabis on COVID-19. The manuscript of the paper has been uploaded on Preprints. However, it signifies that the research has not yet been peer reviewed or been published in a journal.

As per sources close to the matter, the study is focused on how different cannabis extracts affect TMPRSS2 and ACE2 proteins. These proteins are rooted into the cellular membrane and are the main gateway for the coronavirus to enter host cells. Used by the researchers, the C. sativa has been analyzed for modulating the levels of these enzymes.

Initial data indicate that 13 cannabis sativa extracts which are high in the anti-inflammatory cannabinoid cannabidiol can modulate ACE2 expression in coronavirus target tissues and may also down-regulate TMPRSS2 proteins. The results establish that these high-cannabinoid C. sativa lines showcase potential to be a safe and useful addition for the treatment of COVID-19.

Estimates suggests that they could be potentially utilized to develop preventative treatments in the form of a throat gargle or mouthwash product for clinical as well as home use.

 

Source credit: https://www.uleth.ca/unews/article/u-l-scientists-develop-new-medical-cannabis-cultivars-show-promise-combatting-covid-19-virus#.XqEcDGYzbcu

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
By Akshay Kedari

Chinese biotechnology company, CStone Pharmaceuticals has recently announced that it has completed the Share Subscription Agreement with Pfizer Inc. for its newly issued shares worth US$200 million. The move furthers the biotech’s multifaceted ...

Researchers bag $6Mn grant to study the link between Parkinson’s & aging
Researchers bag $6Mn grant to study the link between Parkinson’s & aging
By Akshay Kedari

A three-year grant worth $6 million, funded by the Michael J. Fox Foundation, was recently awarded to a collaborative research team from Michigan’s Van Andel Institute (VAI) and the University of Minnesota Medical School. The grant was given th...

EY announces availability of OpsChain Network Procurement solution
EY announces availability of OpsChain Network Procurement solution
By Akshay Kedari

Ernst & Young (EY), a global professional services network, has recently announced the availability of a first-of-its-kind OpsChain Network Procurement solution. The solution has been built on the company’s OpsChain platform. It will enabl...

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...